{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-037575","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2026-08-13T11:30:14+00:00","discovered_at":"2026-08-13T11:35:00.261059+00:00","generated_at":"2026-08-13T11:35:34.846521+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Abeona Q2 ZEVASKYN revenue up 31% QoQ to $11.4M; net loss widens to $20.2M","bullets":["ZEVASKYN net revenue $11.4M in Q2 2026, up 31% QoQ from $8.7M in Q1; revenue recognized for 4 of 5 treated patients","Net loss $(20.2)M ($0.35/share) vs $(17.1)M ($0.30/share) in Q1; cash $146.8M at June 30, down from $191.4M at Dec 31","QTC network expanded to 7 sites; CHOP, NewYork-Presbyterian/Columbia activated in Q2, Cincinnati Children's in Q3","CMS granted NTAP status for ZEVASKYN effective Oct 1, 2026, supporting hospital adoption and Medicare access","R&D expenses fell to $5.0M from $9.6M (Q1 included $7.0M one-time ABO-701 in-licensing cost); SG&A $15.8M vs $19.5M"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-037575","json":"https://secwatch.observer/filing/0001493152-26-037575.json","markdown":"https://secwatch.observer/filing/0001493152-26-037575.md","text":"https://secwatch.observer/filing/0001493152-26-037575.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/0001493152-26-037575-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000149315226037575/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:35:34.846521+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}